anokion
Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance.
Total raised
€70M
€70,039,261
Funding rounds
2
Investors
1
distinct backers
Active since
2019-09
latest 2022-10
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood22
base rate 30% for Other
- ▼ Overdue vs cohort gap
- ▼ Low backer re-investment
Exit likelihood16
base rate 12% (2+ rounds)
- ▲ €30M+ raised
- ▲ 16y since founding
Timing: overdue vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-10-19 | Other | €36M | Pfizer Breakthrough Growth Initiative | View deal → |
| 2019-10-01 | Series B | €34M | — | View deal → |
Investors
1Related news
- Anokion Raises $35M in Equity Funding from Pfizerfinsmes.com · 2022-10
- unquote.com
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Roivant Sciences€1.2BSwitzerland · Healthtech
- CMR Surgical€1.2BUK · Healthtech
- Climeworks€920MSwitzerland · Cleantech
- Energy Vault€896MSwitzerland · Energy